The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
 
Jacob J. Adashek
No Relationships to Disclose
 
Shumei Kato
Honoraria - Roche
Consulting or Advisory Role - Foundation Medicine; Pfizer/EMD Serono
Speakers' Bureau - Bayer
Research Funding - ACT Genomics; Konica Minolta; OmniSeq; Sysmex
 
Sarabjot Pabla
Employment - Omniseq
Patents, Royalties, Other Intellectual Property - Patent pending at Omniseq (Inst)
 
Mary Nesline
Employment - OmniSeq
 
Jeffrey M. Conroy
Employment - OmniSeq
Leadership - OmniSeq
Stock and Other Ownership Interests - OmniSeq
Research Funding - OmniSeq
Patents, Royalties, Other Intellectual Property - Oncology based gene expression signatures
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape
 
Paul DePietro
Employment - OmniSeq
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Bicara Therapeutics; Biological Dynamics; Eisai; EOM Pharmaceuticals; Iylon; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Prosperdtx; Roche; TD2/Volastra; Turning Point Therapeutics; XBiotech
Research Funding - Biological Dynamics; Boehringer Ingelheim; Debiopharm Group; Foundation Medicine; Genentech; Grifols; Guardant Health; Incyte; Konica Minolta; MedImmune; Merck Serono; Omniseq; Pfizer; Sequenom; Takeda; TopAlliance BioSciences Inc